DOI: 10.1093/cid/cit164; PMCID: PMC4618548
Background We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and Rotarix (RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and emergency department (ED) visits in US children.
Methods We enrolled children vaccine, age, ethnicity, genotype, and clinical setting.
Results RV5-specific analyses included 359 rotavirus cases and 1811 rotavirus-negative AGE controls. RV1-specific analyses included 60 rotavirus cases and 155 rotavirus-negative AGE controls. RV5 and RV1 were 84% (95% confidence interval [CI], 78%-88%) and 70% (95% CI, 39%-86%) effective, respectively, against rotavirus-associated ED visits and hospitalizations combined. By clinical setting, RV5 VE against ED and inpatient rotavirus-associated visits was 81% (95% CI, 70%-84%) and 86% (95% CI, 74%-91%), respectively. RV1 was 78% (95% CI, 46%-91%) effective against ED rotavirus disease; study power was insufficient to evaluate inpatient RV1 VE. No waning of immunity was evident during the first 4 years of life for RV5, nor during the first 2 years of life for RV1. RV5 provided genotype-specific protection against each of the predominant strains (G1P, G2P, G3P, G12P), while RV1 VE was statistically significant for the most common genotype, G3P.
Conclusions Both RV5 and RV1 significantly protected against medically attended rotavirus gastroenteritis in this real-world assessment. © 2013 The Author.
Clinical Infectious Diseases
New Vaccine Surveillance Network, RotaTeq, rotavirus, vaccine
Payne, D. C., Boom, J. A., Staat, M., Edwards, K. M., Szilagyi, P. G., Klein, E. J., Selvarangan, R., Azimi, P. H., Harrison, C. J., Moffatt, M., Johnston, S. H., Sahni, L. C., Baker, C. J., Rench, M. A., Donauer, S., McNeal, M., Chappell, J., Weinberg, G. A., Tasslimi, A., Tate, J. E., Wikswo, M., Curns, A. T., Sulemana, I., Mijatovic-Rustempasic, S., Esona, M. D., Bowen, M. D., Gentsch, J. R., Parashar, U. D. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of>age, 2009-2011 Clinical Infectious Diseases 57, 13-20 (2013).